Current Cardiovascular DrugsWilliam H. Frishman, Angela Cheng-Lai, James Nawarskas Springer Science & Business Media, 2005 M01 4 - 384 pages This fourth edition of Current Cardiovascular Drugs is designed to provide an updated practical compendium of current knowledge regarding cardiovascular drug therapy in a concise, easily readable format. The book is organized into chapters by drug class, and details the pharmacologic characteristics of specific treatment entities. The clinical efficacy and limitations of the various drug therapies are discussed using supportive reference material from the most authoritative sources and published clinical trials. The book is for practicing physicians, physician's assistants, pharmacists, nurse practitioners, nurses, and residents. |
From inside the book
Results 1-5 of 85
Page v
... trials . Current Cardiovascular Drugs is not designed to replace traditional textbooks of cardiovascular medicine , or to resolve ongoing controversies in patient manage- ment . Rather , its purpose is to provide a user - friendly ...
... trials . Current Cardiovascular Drugs is not designed to replace traditional textbooks of cardiovascular medicine , or to resolve ongoing controversies in patient manage- ment . Rather , its purpose is to provide a user - friendly ...
Page 1
... trials demonstrated the use of oral atenolol in relieving ischemia and improving outcomes in patients with documented silent myocardial ischemia . These studies compared atenolol monotherapy with placebo , calcium - channel blocker ...
... trials demonstrated the use of oral atenolol in relieving ischemia and improving outcomes in patients with documented silent myocardial ischemia . These studies compared atenolol monotherapy with placebo , calcium - channel blocker ...
Page 3
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Page 7
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Page 18
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Other editions - View all
Common terms and phrases
ACE inhibitors acid acute adjustment is required administered agents amiodarone angina antiarrhythmic antihypertensive artery aspirin atrial fibrillation benefits vs risk beta-blockers Bioavailability blockers blood bradycardia breast milk Breastfeeding not recommended BRIEF INDICATIONS cardiac cardiovascular cholesterol CONTRAINDICATIONS coronary decrease digoxin diltiazem disease diuretics dizziness dosage adjustment dose with caution dose with frequent DRUG INTERACTIONS Duration of action edema Effect of food efficacy Elimination half-life enalapril established Elderly excreted in breast excretion in milk Frishman WH GROUPS Race headache heart failure heart rate heparin Hepatic impairment hypertension hypotension increase the effect/toxicity infusion initial dose intravenous liver lovastatin lower dose Metabolism metabolites mg once daily mg/d myocardial infarction nausea Onset of action oral OVERDOSE Supportive PATIENT INFORMATION Peak effect PHARMACODYNAMICS Duration PHARMACOKINETICS AND PHARMACODYNAMICS plasma platelet Pregnancy Protein binding receptor reduced safety and effectiveness side effects SPECIAL GROUPS Race tablets tachycardia therapy thiazide trandolapril treatment trial vascular verapamil Volume of distribution
Popular passages
Page 350 - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the...